Iron accumulation secondary to mitophagy dysfunction, both in PINK1- and PRKN-mutated PD patients, has raised the possibility to employ iron chelator drugs in this subgroup of PD patients [87,89]. This evidence concerns the gene PRKN and Parkinson disease.